Fulcrum Non Currrent Assets Other vs Other Stockholder Equity Analysis

FULC Stock  USD 3.77  0.11  2.84%   
Fulcrum Therapeutics financial indicator trend analysis is much more than just examining Fulcrum Therapeutics latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Fulcrum Therapeutics is a good investment. Please check the relationship between Fulcrum Therapeutics Non Currrent Assets Other and its Other Stockholder Equity accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Fulcrum Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.
For information on how to trade Fulcrum Stock refer to our How to Trade Fulcrum Stock guide.

Non Currrent Assets Other vs Other Stockholder Equity

Non Currrent Assets Other vs Other Stockholder Equity Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Fulcrum Therapeutics Non Currrent Assets Other account and Other Stockholder Equity. At this time, the significance of the direction appears to have no relationship.
The correlation between Fulcrum Therapeutics' Non Currrent Assets Other and Other Stockholder Equity is 0.01. Overlapping area represents the amount of variation of Non Currrent Assets Other that can explain the historical movement of Other Stockholder Equity in the same time period over historical financial statements of Fulcrum Therapeutics, assuming nothing else is changed. The correlation between historical values of Fulcrum Therapeutics' Non Currrent Assets Other and Other Stockholder Equity is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Non Currrent Assets Other of Fulcrum Therapeutics are associated (or correlated) with its Other Stockholder Equity. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Other Stockholder Equity has no effect on the direction of Non Currrent Assets Other i.e., Fulcrum Therapeutics' Non Currrent Assets Other and Other Stockholder Equity go up and down completely randomly.

Correlation Coefficient

0.01
Relationship DirectionPositive 
Relationship StrengthInsignificant

Non Currrent Assets Other

Assets that are not physical or tangible, expected to provide value for more than one year, and not easily converted into cash, such as long-term investments or patents.

Other Stockholder Equity

Most indicators from Fulcrum Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Fulcrum Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Fulcrum Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.
For information on how to trade Fulcrum Stock refer to our How to Trade Fulcrum Stock guide.The current year's Sales General And Administrative To Revenue is expected to grow to 15.60, whereas Selling General Administrative is forecasted to decline to about 25.3 M.
 2018 2019 2023 2024 (projected)
Interest Income518K1.5M1.7M1.8M
Net Interest Income518K1.5M1.7M1.8M

Fulcrum Therapeutics fundamental ratios Correlations

0.620.811.00.260.930.27-0.42-0.930.810.540.87-0.020.91.00.810.950.920.830.93-0.520.90.990.871.00.7
0.620.740.590.360.660.46-0.41-0.690.520.520.82-0.240.710.610.360.670.610.830.68-0.450.340.680.820.610.53
0.810.740.780.50.810.27-0.51-0.740.930.590.84-0.040.720.810.850.770.660.760.78-0.70.580.780.970.80.49
1.00.590.780.220.930.24-0.38-0.920.790.510.850.00.91.00.810.940.930.80.93-0.50.920.990.831.00.71
0.260.360.50.220.140.74-0.95-0.040.280.880.39-0.680.090.260.270.15-0.060.560.080.1-0.090.180.550.290.08
0.930.660.810.930.140.28-0.25-0.970.840.410.78-0.040.920.940.780.960.870.760.99-0.510.860.940.840.920.75
0.270.460.270.240.740.28-0.74-0.190.090.750.32-0.960.230.26-0.030.260.010.640.230.460.030.230.430.290.23
-0.42-0.41-0.51-0.38-0.95-0.25-0.740.2-0.29-0.98-0.560.63-0.29-0.41-0.29-0.32-0.11-0.71-0.22-0.06-0.06-0.33-0.61-0.45-0.25
-0.93-0.69-0.74-0.92-0.04-0.97-0.190.2-0.73-0.38-0.83-0.07-0.98-0.92-0.7-0.99-0.93-0.77-0.990.56-0.84-0.95-0.8-0.91-0.84
0.810.520.930.790.280.840.09-0.29-0.730.370.680.10.650.810.910.740.670.590.78-0.680.730.770.850.790.38
0.540.520.590.510.880.410.75-0.98-0.380.370.68-0.590.470.530.350.490.260.820.4-0.020.180.470.710.580.42
0.870.820.840.850.390.780.32-0.56-0.830.680.68-0.030.880.860.620.870.790.930.82-0.60.610.870.920.870.66
-0.02-0.24-0.040.0-0.68-0.04-0.960.63-0.070.1-0.59-0.030.05-0.020.220.020.22-0.40.03-0.670.150.01-0.18-0.040.0
0.90.710.720.90.090.920.23-0.29-0.980.650.470.880.050.90.630.990.890.830.96-0.550.760.920.80.90.88
1.00.610.811.00.260.940.26-0.41-0.920.810.530.86-0.020.90.820.940.920.820.93-0.520.90.990.861.00.7
0.810.360.850.810.270.78-0.03-0.29-0.70.910.350.620.220.630.820.720.710.490.74-0.70.740.770.760.80.5
0.950.670.770.940.150.960.26-0.32-0.990.740.490.870.020.990.940.720.90.830.99-0.530.830.950.840.940.85
0.920.610.660.93-0.060.870.01-0.11-0.930.670.260.790.220.890.920.710.90.680.9-0.610.890.960.710.910.73
0.830.830.760.80.560.760.64-0.71-0.770.590.820.93-0.40.830.820.490.830.680.78-0.290.550.820.90.840.65
0.930.680.780.930.080.990.23-0.22-0.990.780.40.820.030.960.930.740.990.90.78-0.550.850.940.820.920.81
-0.52-0.45-0.7-0.50.1-0.510.46-0.060.56-0.68-0.02-0.6-0.67-0.55-0.52-0.7-0.53-0.61-0.29-0.55-0.42-0.54-0.58-0.49-0.37
0.90.340.580.92-0.090.860.03-0.06-0.840.730.180.610.150.760.90.740.830.890.550.85-0.420.90.60.880.54
0.990.680.780.990.180.940.23-0.33-0.950.770.470.870.010.920.990.770.950.960.820.94-0.540.90.840.980.72
0.870.820.970.830.550.840.43-0.61-0.80.850.710.92-0.180.80.860.760.840.710.90.82-0.580.60.840.860.58
1.00.610.81.00.290.920.29-0.45-0.910.790.580.87-0.040.91.00.80.940.910.840.92-0.490.880.980.860.71
0.70.530.490.710.080.750.23-0.25-0.840.380.420.660.00.880.70.50.850.730.650.81-0.370.540.720.580.71
Click cells to compare fundamentals

Fulcrum Therapeutics Account Relationship Matchups

Fulcrum Therapeutics fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets110.4M129.6M235M226.7M257.7M164.9M
Other Current Liab5.9M7.7M74K6.9M6.5M4.5M
Total Current Liabilities12.1M26.7M19.2M16.7M13.7M15.0M
Total Stockholder Equity87.2M95.2M211.5M198.9M235.2M142.3M
Other Liab11.1M7.7M4.3M197K177.3K168.4K
Net Tangible Assets87.2M95.2M211.5M198.9M228.8M240.2M
Property Plant And Equipment Net87.9M8.4M7.4M16.0M12.4M16.6M
Net Debt(96.7M)(57.0M)(35.4M)(21.7M)(14.7M)(15.5M)
Retained Earnings(150.8M)(221.6M)(302.5M)(412.3M)(509.7M)(484.2M)
Accounts Payable2.2M4.1M4.8M3.6M2.8M3.2M
Cash96.7M57.1M35.4M35.1M25.6M36.9M
Non Current Assets Total10.4M16.7M9.0M19.2M15.5M13.4M
Non Currrent Assets Other(78.7M)7.2M542K2.1M3.1M3.3M
Other Assets1.2M1.7M1.6M3.2M3.7M3.9M
Cash And Short Term Investments96.7M112.9M218.2M202.9M236.2M147.7M
Net Receivables111K2.7M4.1M1.1M2.2M1.7M
Common Stock Total Equity23K28K41K52K59.8K62.8K
Common Stock Shares Outstanding11.0M25.4M35.4M45.0M61.3M32.4M
Liabilities And Stockholders Equity110.4M129.6M235M226.7M257.7M164.9M
Non Current Liabilities Total11.1M7.7M4.3M11.0M8.8M7.7M
Capital Surpluse237.9M316.8M514.4M612.0M703.8M739.0M
Capital Lease Obligations46K50K17K13.4M10.8M11.4M
Inventory3.0M(2.8M)(473K)(852K)(766.8K)(728.5K)
Other Current Assets284K74K4.2M3.5M3.7M1.9M
Other Stockholder Equity237.9M316.8M514.4M612.0M744.9M404.7M
Total Liab23.3M34.4M23.5M27.7M22.5M22.7M
Net Invested Capital87.2M95.2M211.5M198.9M235.2M136.8M
Property Plant And Equipment Gross9.2M8.4M7.4M6.9M25.2M26.4M
Total Current Assets100.1M112.9M226.0M207.5M242.2M151.5M
Accumulated Other Comprehensive Income(110.4M)(2K)(397K)(797K)(136K)(142.8K)
Non Current Liabilities Other150K55K3.1M197K226.6K215.2K
Net Working Capital87.9M92.8M206.8M190.8M228.5M137.5M
Short Term Debt50K17K9.6M5.2M4.4M3.0M
Common Stock23K28K41K52K62K35.0K
Property Plant Equipment9.2M8.4M7.4M6.9M7.9M8.3M
Short Long Term Debt Total50K17K469K13.4M10.8M11.4M
Current Deferred Revenue4.0M14.9M4.7M934K1.4M1.4M
Capital Stock23K28K41K52K62K40.7K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Fulcrum Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Fulcrum Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Fulcrum Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Fulcrum Therapeutics Stock:
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Fulcrum Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.
For information on how to trade Fulcrum Stock refer to our How to Trade Fulcrum Stock guide.
You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Fulcrum Therapeutics. If investors know Fulcrum will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Fulcrum Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.29)
Revenue Per Share
1.317
Quarterly Revenue Growth
89.909
Return On Assets
(0.07)
Return On Equity
(0.07)
The market value of Fulcrum Therapeutics is measured differently than its book value, which is the value of Fulcrum that is recorded on the company's balance sheet. Investors also form their own opinion of Fulcrum Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Fulcrum Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Fulcrum Therapeutics' market value can be influenced by many factors that don't directly affect Fulcrum Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Fulcrum Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Fulcrum Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Fulcrum Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.